AZIN1 and bladder transitional cell carcinoma: For disease‐free survival (DFS), lower expression of AZIN1 in BLCA and KIRP indicated longer DFS, but KIRC patients with lower AZIN1 expression indicated poorer clinical outcomes (Figure 1D), which is consistent with AZIN1's prognostic role of OS in KIRC.